Next Article in Journal / Special Issue
MicroRNAs as Biomarkers in Cancer
Previous Article in Journal
A Review of Heating and Temperature Control in Microfluidic Systems: Techniques and Applications
Previous Article in Special Issue
Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma
Article Menu

Export Article

Open AccessArticle
Diagnostics 2013, 3(1), 68-83; doi:10.3390/diagnostics3010068

TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer

1
Graduate School of Environmental Engineering, the University of Kitakyushu, 1-1 Hibikino, Wakamatsu-ku, Kitakyushu 808-0135, Japan
2
Shinkou Seiki Co. Ltd., 1-18-3, Maidashi, Higashi-ku, Fukuoka 812-8581, Japan
3
Department of Veterinary Pathology, School of Veterinary Medicine, Rakuno Gakuen University, 582, Midorimachi, Bunkyodai, Ebetsu 069-8501, Japan
*
Author to whom correspondence should be addressed.
Received: 8 December 2012 / Revised: 31 December 2012 / Accepted: 15 January 2013 / Published: 16 January 2013
(This article belongs to the Special Issue Molecular Biomarkers for Cancer Targeted Therapeutics)
View Full-Text   |   Download PDF [474 KB, uploaded 16 January 2013]   |  

Abstract

An analytical TD-GC-MS method was developed and used for the assessment of volatile organic compounds (VOCs) released from the blood plasma of dogs with/without cancer. VOCs released from 40 samples of diseased blood and 10 control samples were compared in order to examine the difference between both sample groups that were showing qualitatively similar results independent from the disease’s presence. However, mild disturbances in the spectra of dogs with cancer in comparison with the control group were observed, and six peaks (tentatively identified by comparison with mass spectral library as hexanal, octanal, toluene, 2-butanone, 1-octen-3-ol and pyrrole) revealed statistically significant differences between both sample groups, thereby suggesting that these compounds are potential biomarkers that can be used for cancer diagnosis based on the blood plasma TD-GC-MS analysis. Statistical comparison with the application of principal component analysis (PCA) provided accurate discrimination between the cancer and control groups, thus demonstrating stronger biochemical perturbations in blood plasma when cancer is present. View Full-Text
Keywords: dog blood plasma; TD-GC-MS; volatile organic compounds; cancer markers dog blood plasma; TD-GC-MS; volatile organic compounds; cancer markers
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Selyanchyn, R.; Nozoe, T.; Matsui, H.; Kadosawa, T.; Lee, S.-W. TD-GC-MS Investigation of the VOCs Released from Blood Plasma of Dogs with Cancer. Diagnostics 2013, 3, 68-83.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diagnostics EISSN 2075-4418 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top